WG
TBPH

Winton Group’s Theravance Biopharma TBPH Stock Holding History

Winton Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,520
Closed -$414K – 1481
2026
Q1 		$414K Sell
25,520
-39,250
-61% -$694K 0.01% 770
2025
Q4 		$1.21M Sell
64,770
-11,772
-15% -$195K 0.04% 416
2025
Q3 		$1.12M Buy
+76,542
New +$967K 0.04% 416

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Winton Group's TBPH Position: Q2 2026 in Review

Winton Group sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 25,520 shares — an estimated $414K sold.

Winton Group first reported a position in TBPH in Q3 2025 and held it in 3 quarters. The position peaked at $1.21M in Q4 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Winton Group reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 25,520 Theravance Biopharma shares in Q2 2026, an estimated $414K.
  • Winton Group first reported a position in Theravance Biopharma in Q3 2025 and held it in 3 quarters.
  • Winton Group's Theravance Biopharma position peaked at $1.21M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.